Market research
SVRA Savara Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- P/E ratio
- Not available
- Analyst target
- 10.9375
- Dividend yield
- Not available
- Beta
- 0.26
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US8051111016
- P/E ratio
- Not available
- Analyst target
- 10.9375
- Dividend yield
- Not available
- Beta
- 0.26
About
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SVRA discussion.
5 years, 4 months ago
Savara Inc is currently in a long term downtrend where the price is trading 3.2% below its 200 day moving average.
From a valuation standpoint, the stock is 60.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 528.5.
Savara Inc's total revenue rose by inf% to $1K since the same quarter in the previous year.
Its net income has increased by 56.7% to $-14M since the same quarter in the previous year.
Finally, its free cash flow fell by 23.6% to $-12M since the same quarter in the previous year.
Based on the above factors, Savara Inc gets an overall score of 3/5.